BIM
MRNS

Bogle Investment Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Bogle Investment Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-95,655
Closed -$2.25M – 371
2017
Q3 		$2.25M Buy
+95,655
New +$1.07M 0.15% 149

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bogle Investment Management's MRNS Position: Q4 2017 in Review

Bogle Investment Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2017, closing a stake of 95,655 shares — an estimated $2.25M sold.

Bogle Investment Management first reported a position in MRNS in Q3 2017 and held it in 1 quarter. The position peaked at $2.25M in Q3 2017. 65 funds tracked by Wall St. Rank hold MRNS as of Q4 2017.

  • Bogle Investment Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Bogle Investment Management sold 95,655 Marinus Pharmaceuticals, Inc shares in Q4 2017, an estimated $2.25M.
  • Bogle Investment Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 1 quarter.
  • Bogle Investment Management's Marinus Pharmaceuticals, Inc position peaked at $2.25M in Q3 2017.
  • 65 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2017.

Based on Bogle Investment Management's 13F filing for Q4 2017, filed 13 Feb 2018.